Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14852911 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL5525066 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL16021494 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL7152285 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL7652816 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL8829594 | 1.00 | CA12 (0.50) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL7957437 | 0.86 | CA12 (0.39) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL15196950 | 0.85 | CA12 (0.54) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL4289259 | 0.85 | TYR (0.62) | CA12CA9TYRNR1H3AKR1B1 | |
| SCHEMBL10103003 | 0.85 | CA12 (0.54) | CA12CA9TYRNR1H3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492335-B1 | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| EP-0934329-B1 | GLYCOCONJUGATES FROM MODIFIED CAMPTOTHECIN DERIVATES (20-O-LINKAGE) | BAYER AG (DE) | 2001-12-12 | — | — | EP | disclosed |
| EP-0939765-B1 | GLYCOCONJUGATES OF MODIFIED CAMPTOTHECIN DERIVATIVES (A- OR B-RING LINKAGE) | BAYER AG (DE) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001058932-A1 | CYTOSTATIC AGENT GLYCOCONJUGATE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-16 | — | — | WO | disclosed |
| US-6156754-A | Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage) | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-05 | — | — | US | disclosed |
| EP-0819135-B1 | SUGAR-MODIFIED CYTOSTATICS | BAYER AG (DE) | 1999-11-17 | — | — | EP | disclosed |
| EP-0819135-A1 | SUGAR-MODIFIED CYTOSTATICS | BAYER AG (DE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031532-A1 | SUGAR-MODIFIED CYTOSTATICS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-10-10 | — | — | WO | disclosed |
| US-5286629-A | Using product with residue of rhamnose, galactose, or galactose 6-phosphate | PARFUMS CHRISTIAN DIOR (FR) | 1994-02-15 | — | — | US | disclosed |